A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection

Cancer Medicine

Volumn 3, Issue 4, 2014, Pages 900-908

  Cata, Juan P ^a   Keerty, Visesh ^a   Keerty, Dinesh ^b   Feng, Lei ^a   Norman, Peter H ^a   Gottumukkala, Vijaya ^a   Mehran, John R ^a   Engle, Mitchel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Wright Center for Graduate Medical Education   (United States)

Author keywords

Neoplasms; Opioids; Recurrence; Surgery

Indexed keywords

FENTANYL; HYDROMORPHONE; NARCOTIC ANALGESIC AGENT; REMIFENTANIL; SUFENTANIL;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; DEMOGRAPHY; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; LOBECTOMY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; THORACOTOMY; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DOSE RESPONSE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

ANALGESICS, OPIOID; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENTANYL; HUMANS; INTRAOPERATIVE PERIOD; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84919849931     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.236     Document Type: Article

References (30)

1. Cata, J. P., V. Gottumukkala, and D.I. Sessler . 2011. How regional analgesia might reduce postoperative cancer recurrence. Eur. J. Pain Suppl. 5:345-355.
2. Lennon, F. E., J. Moss, and P. A. Singleton . 2012. The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology 116:940-945.
3. Mathew, B., F. E. Lennon, J. Siegler, T. Mirzapoiazova, N. Mambetsariev, S. Saad, et al. 2011. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth. Analg. 112:558-567.
4. Bortsov, A. V., R. C. Millikan, I. Belfer, R. L. Boortz-Marx, H. Arora, and S. A. McLean . 2012. mu-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 116:896-902.
5. Wang, S., Y. Li, X. D. Liu, C. X. Zhao, and K. Q. Yang . 2013. Polymorphism of A118G in mu-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int. J. Clin. Oncol. 18:666-669.
6. Cata, J. P., M. Bauer, T. Sokari, M.F. Ramirez, D. Mason, G. Plautz, et al. 2013. Effects of surgery, general anesthesia, and perioperative epidural analgesia on the immune function of patients with non-small cell lung cancer. J. Clin. Anesth. 25:255-262.
7. Sessler, D. I., S. Ben-Eliyahu, E. J. Mascha, M. O. Parat, and D. J. Buggy . 2008. Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Contemp. Clin. Trials. 29:517-526.
8. Chen, W.-K., and C.-H. Miao . 2013. The effect of anesthetic technique on survival in human cancers: a meta-analysis of retrospective and prospective studies. PLoS ONE 8:e56540.
9. Lillemoe, K. D., J. L. Cameron, H. S. Kaufman, C. J. Yeo, H. A. Pitt, and P. K. Sauter . 1993. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann. Surg. 217:447-455, discussion 456-447.
10. Smith, T. J., P. S. Staats, T. Deer, L. J. Stearns, R. L. Rauck, R. L. Boortz-Marx, et al. 2002. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J. Clin. Oncol. 20:4040-4049.
11. Lissoni, P., S. Meregalli, V. Fossati, S. Barni, G. Tancini, P. Barigozzi, et al. 1993. Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy. Tumori 79:198-201.
12. Biki, B., E. Mascha, D. C. Moriarty, J. M. Fitzpatrick, D. I. Sessler, and D. J. Buggy . 2008. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 109:180-187.
13. Exadaktylos, A. K., D. J. Buggy, D. C. Moriarty, E. Mascha, and D. I. Sessler . 2006. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 105:660-664.
14. Myles, P., P. Peyton, B. Silbert, J. Hunt, J. R. Rigg, and D. I. Sessler . 2011. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 342:d1491.
15. Gottschalk, A., J. Ford, C. Regelin, J. You, E. J. Mascha, D. I. Sessler, et al. 2010. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology 113:27-34.
16. Cata, J. P., V. Gottumukkala, D. Thakar, D. Keerty, R. Gebhardt, and D. D. Liu . 2014. Effects of postoperative epidural analgesia on recurrence-free and overall survival in patients with nonsmall cell lung cancer. J. Clin. Anesth. 26:3-17.
17. Forget, P., B. Tombal, J. L. Scholtes, J.P. Machiels, B. Nussbaum, C. Legrand, et al. 2011. Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer? Eur. J. Anaesthesiol. 28:830-835.
18. Zylla, D., B. L. Gourley, D. Vang, S. Jackson, S. Boatman, B. Lindgren, et al. 2013. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 119:4103-4110.
19. Forget, P., J. Vandenhende, M. Berliere, J. P. Machiels, B. Nussbaum, C. Legrand, et al. 2010. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth. Analg. 110:1630-1635.
20. Madar, I., B. Bencherif, J. Lever, R. F. Heitmiller, S. C. Yang, M. Brock, et al. 2007. Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. J. Nucl. Med. 48:207-213.
21. Baltayiannis, N., M. Chandrinos, D. Anagnostopoulos, P. Zarogoulidis, K. Tsakiridis, A. Mpakas, et al. 2013. Lung cancer surgery: an up to date. J. Thorac. Dis. 5:S425-S439.
22. Lennon, F. E., T. Mirzapoiazova, B. Mambetsariev, R. Salgia, J. Moss, and P. A. Singleton . 2012. Overexpression of the mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology 116:857-867.
23. Maneckjee, R., and J. D. Minna . 1990. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc. Natl Acad. Sci. USA 87:3294-3298.
24. Farooqui, M., Y. Li, T. Rogers, T. Poonawala, R. J. Griffin, C.W. Song, et al. 2007. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br. J. Cancer 97:1523-1531.
25. Hanahan, D., and R. Weinberg . 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
26. Na, I. I., H. R. Kim, J. K. Lee, S.H. Park, C.H. Kim, J. S. Koh, et al. 2012. Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer. J. Cancer Res. Ther. 8:373-378.
27. Fujioka, N., J. Nguyen, C. Chen, Y. Li, T. Pasrija, G. Niehans, et al. 2011. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth. Analg. 113:1353-1364.
28. Cata, J. P., M. Bauer, T. Sokari, M.F. Ramirez, D. Mason, G. Plautz, et al. 2013. Effects of surgery, general anesthesia, and perioperative epidural analgesia on the immune function of patients with non-small cell lung cancer. J. Clin. Anesth. 25:255-262.
29. Yardeni, I. Z., B. Beilin, E. Mayburd, Y. Alcalay, and H. Bessler . 2008. Relationship between fentanyl dosage and immune function in the postoperative period. J. Opioid Manag. 4:27-33.
30. Nosotti, M., P. Rebulla, D. Riccardi, A. Baisi, N. Bellaviti, L. Rosso, et al. 2003. Correlation between perioperative blood transfusion and prognosis of patients subjected to surgery for stage I lung cancer. Chest 124:102-107.